비후성 및 켈로이드성 반흔 치료 시장 규모, 점유율 및 동향 분석 보고서 : 반흔 유형별, 제품 유형별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Hypertrophic And Keloid Scar Treatment Market Summary

The global hypertrophic and keloid scar treatment market size was valued at USD 763.2 million in 2025 and is projected to grow from USD 842.7 million in 2026 to USD 1,680.2 million by 2033, at a CAGR of 10.4% from 2026 to 2033. Asia Pacific held the largest market share of 46.1% in 2025. The increase in the number of road accidents & burn cases, along with technological advancements and growing awareness regarding the availability of aesthetic surgery, are major factors boosting the industry adoption over the years.

The global increase in the number of road accidents & burn incidence is anticipated to boost the hypertrophic and keloid scar treatment industry. For instance, according to the Association for Safe International Road Travel, approximately 1.35 million people die in road accidents every year. Moreover, as per a similar source, in the U.S., 4.4 million people get seriously injured. The increasing global burden of acne and its long-term secondary effects are key drivers of growth in the hypertrophic and keloid scars industry. In February 2024, a landmark global epidemiology study was published in the Journal of the American Academy of Dermatology (JAAD) by Pierre Fabre Laboratories as part of the ALL-project initiative. This large-scale study surveyed 50,552 adults across 20 countries, representing over 50% of the world's population, making it one of the most comprehensive assessments of acne prevalence and its societal impact.

The study found that global acne prevalence stands at 20.5%, meaning one in five individuals worldwide is affected. Prevalence is highest among adolescents and young adults (16-24 years) at 28.3% and remains high in adults aged 25-39 years at 19.3%. Women are more affected than men (23.6% vs. 17.5%), broadening the long-term consumer base for post-acne scar and pigmentation treatments.

Geographically, the highest prevalence rates were observed in Latin America (23.9%), East Asia (20.2%), Africa (18.5%), and the Middle East (16.1%), while Europe (9.7%) and Australia (10.8%) reported lower rates. Many high-prevalence regions overlap with populations predisposed to PIH and hypertrophic scarring, strengthening demand for targeted topical therapies.

Global Hypertrophic And Keloid Scar Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the hypertrophic and keloid scar treatment market report based on scar type, product, end use, and region:

• Scar type Outlook (Revenue, USD Million, 2021 - 2033)
• Hypertrophic Scar
• Keloid Scar
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Topical Products
  • Silicone Sheets
  • Creams
  • Gels
  • Others
• Laser Products
  • Pulsed Dye Lasers
  • CO2 Lasers
  • Others
• Injectables
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Business to Business (B2B)
  • Hospitals
  • Clinics
• Business to Consumers (B2C)
  • Pharmacies
  • Online/E-commerce
  • Hypermarkets &Supermarkets
  • Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Scar Type
  • 1.2.2. Product
  • 1.2.3. End Use
  • 1.2.4. Region scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Scar type outlook
  • 2.2.2. Product outlook
  • 2.2.3. End use outlook
  • 2.2.4. Region outlook
• 2.3. Competitive Insights

Chapter 3. Hypertrophic & Keloid Scar Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Hypertrophic & Keloid Scar Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Hypertrophic & Keloid Scar Treatment Market: Scar Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Hypertrophic & Keloid Scar Treatment Market: Scar Type Movement Analysis
• 4.3. Hypertrophic & Keloid Scar Treatment Market by Scar Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Hypertrophic Scar
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Keloid Scar
  • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Hypertrophic & Keloid Scar Treatment Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Hypertrophic & Keloid Scar Treatment Market: Application Movement Analysis
• 5.3. Hypertrophic & Keloid Scar Treatment Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Topical Products
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Silicone Sheets
    • 5.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Creams
    • 5.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Gels
    • 5.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Others
    • 5.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Laser Products
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.2. Pulsed Dye Lasers
    • 5.6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.3. CO2 Lasers
    • 5.6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.4. Others
    • 5.6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Injectables
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Hypertrophic & Keloid Scar Treatment Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Hypertrophic & Keloid Scar Treatment Market: End Use Movement Analysis
• 6.3. Hypertrophic & Keloid Scar Treatment Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Business to Business (B2B)
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Hospitals
    • 6.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Clinics
    • 6.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Business to Consumers (B2C)
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Pharmacies
    • 6.6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Online/E-commerce
    • 6.6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. Hypermarkets &Supermarkets
    • 6.6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Others
    • 6.6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Hypertrophic & Keloid Scar Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Denmark
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.8. Norway
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. Smith & Nephew
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Product Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. Merz Pharmaceuticals, LLC
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Product Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. Sonoma Pharmaceuticals, Inc.
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Product Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. CCA Industries, Inc.
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Product Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. Newmedical Technology Inc.
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Product Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Molnlycke Health Care AB
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Product Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. Perrigo Company plc
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Product Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. Rejuvaskin/ Scar Heal Inc.
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Product Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. Alliance Pharma PLC
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Product Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. Hanson Medical, Inc.
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Product Benchmarking
    • 8.2.10.4. Strategic Initiatives
  • 8.2.11. Lumenis Be Ltd.
    • 8.2.11.1. Company Overview
    • 8.2.11.2. Financial Performance
    • 8.2.11.3. Product Benchmarking
    • 8.2.11.4. Strategic Initiatives
  • 8.2.12. CYNOSURE
    • 8.2.12.1. Company Overview
    • 8.2.12.2. Financial Performance
    • 8.2.12.3. Product Benchmarking
    • 8.2.12.4. Strategic Initiatives